Clinical Trial Update: Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating imaging with [89Zr]panitumumab-PET/MRI for newly diagnosed metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Metastatic Colon Cancer | Phase 1, Phase 2 | Status: WITHDRAWN